Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones
Launched by PICTERUS AS · Jul 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new tool called Picterus JP that helps to check for neonatal jaundice in newborns using smartphone cameras. Neonatal jaundice is a common condition that causes yellowing of the skin and eyes in babies, and it needs to be monitored closely. The goal of the study is to confirm that this tool works well on different smartphones, making it easier for parents and healthcare providers to use.
To participate in this trial, infants must be between 1 and 14 days old, born after 37 weeks of pregnancy, and weigh at least 2500 grams at birth. However, babies who have any serious health issues, skin problems, or have recently received special light treatment for jaundice are not eligible to join. If your baby qualifies and participates, you can expect a simple and quick screening process to help ensure their health and well-being. This study is currently looking for participants, and it aims to improve the way we monitor jaundice in newborns.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants born with gestational age \> 37 weeks.
- • Birth weight ≥ 2500 grams
- • Age 1 - 14 days
- Exclusion Criteria:
- • Infants showing signs of inborn disease.
- • Infants with skin rash or other skin disease that affects the skin where measurements are performed.
- • Infants transferred to the pediatric ward for medical treatment.
- • Infants that have received phototherapy in the last 24 hours
About Picterus As
Picterus AS is an innovative clinical trial sponsor dedicated to advancing medical research through the development of cutting-edge imaging technologies. Specializing in the integration of artificial intelligence and machine learning with diagnostic imaging, Picterus AS aims to enhance the accuracy and efficiency of clinical trials. By leveraging state-of-the-art methodologies and a commitment to patient-centered outcomes, the company seeks to optimize the drug development process and improve therapeutic interventions across various healthcare sectors. With a focus on collaboration and scientific rigor, Picterus AS is positioned to make significant contributions to the future of medical diagnostics and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trondheim, , Norway
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported